7 results on '"Maddaloni, Luca"'
Search Results
2. Could SP-A and SP-D Serum Levels Predict COVID-19 Severity?
- Author
-
Maddaloni, Luca, Zullino, Veronica, Bugani, Ginevra, Lazzaro, Alessandro, Brisciani, Matteo, Mastroianni, Claudio Maria, Santinelli, Letizia, and Ruberto, Franco
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *ADULT respiratory distress syndrome , *COVID-19 pandemic , *PROGNOSIS , *SERUM - Abstract
Given the various clinical manifestations that characterize Coronavirus Disease 2019 (COVID-19), the scientific community is constantly searching for biomarkers with prognostic value. Surfactant proteins A (SP-A) and D (SP-D) are collectins that play a crucial role in ensuring proper alveolar function and an alteration of their serum levels was reported in several pulmonary diseases characterized by Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis. Considering that such clinical manifestations can also occur during Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, we wondered if these collectins could act as prognostic markers. In this regard, serum levels of SP-A and SP-D were measured by enzyme immunoassay in patients with SARS-CoV-2 infection (n = 51) at admission (T0) and after seven days (T1) and compared with healthy donors (n = 11). SP-D increased in COVID-19 patients compared to healthy controls during the early phases of infection, while a significant reduction was observed at T1. Stratifying SARS-CoV-2 patients according to disease severity, increased serum SP-D levels were observed in severe compared to mild patients. In light of these results, SP-D, but not SP-A, seems to be an eligible marker of COVID-19 pneumonia, and the early detection of SP-D serum levels could be crucial for preventive clinical management. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. The Epidemiology of Anal Human Papillomavirus (HPV) in HIV-Positive and HIV-Negative Women and Men: A Ten-Year Retrospective Observational Study in Rome (Italy).
- Author
-
Fracella, Matteo, Oliveto, Giuseppe, Roberto, Piergiorgio, Cinti, Lilia, Gentile, Massimo, Coratti, Eleonora, D'Ettorre, Gabriella, Cavallari, Eugenio Nelson, Romano, Francesco, Santinelli, Letizia, Maddaloni, Luca, Frasca, Federica, Scagnolari, Carolina, Antonelli, Guido, and Pierangeli, Alessandra
- Subjects
PAPILLOMAVIRUSES ,HUMAN papillomavirus ,HIV-positive women ,ANAL cancer ,HIV-positive men ,SCIENTIFIC observation - Abstract
Human papillomaviruses (HPVs) commonly infect the anogenital mucosa; most infections are transient, but a fraction of those caused by high-risk (HR) types persist and may lead to anogenital cancer. The epidemiology of HPV genotypes in anal infections in groups at different risk for anal cancer has not been well described in Italy. This retrospective study reports the results of HPV DNA testing and complete genotyping performed on anal swabs from 691 female and male patients attending proctology clinics in Rome during 2012–2021; one-third had repeated testing. Cumulative HPV positivity in 1212 anal swabs was approximately 60%, was not age related, and showed an increasing trend over the study period. HPV rates differed significantly by sex and HIV status: HIV-negative women had the lowest (43.6%) and HIV-positive men the highest (83.5%) HPV prevalence. HIV-positive men had more oncogenic HPV genotypes detected, more multiple infections, and the highest frequency of persistent infections. Two-thirds of all infections were vaccine-preventable. This study found that anal HPV infection rates are still elevated and even increasing in groups at low and high risk of developing anal cancer. Prevention programs need to be improved to reduce rates of anal infection in young women and men. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort.
- Author
-
Lazzaro, Alessandro, Bianchini, Diana, Gentilini Cacciola, Elio, Mezzaroma, Ivano, Falciano, Mario, Andreoni, Carolina, Fimiani, Caterina, Santinelli, Letizia, Maddaloni, Luca, Bugani, Ginevra, Ceccarelli, Giancarlo, Mastroianni, Claudio Maria, and d'Ettorre, Gabriella
- Subjects
TENOFOVIR ,WEIGHT gain ,EMTRICITABINE ,HIV-positive persons ,BLOOD lipids ,KIDNEY physiology ,IMMUNITY - Abstract
Background: Bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) is a recommended once-daily single-tablet regimen for the treatment of people living with HIV (PLWH). We aimed to assess efficacy, safety, and tolerability of BIC/FTC/TAF among PLWH, with a specific focus on people older than 55 years. Methods: We recruited an observational retrospective real-life cohort, including all PLWH who underwent a therapeutic switch to BIC/FTC/TAF, independently from the previous treatment regimen (the BICTEL cohort). Longitudinal nonparametric analyses and linear models were built. Results: After 96 weeks of follow-up, 164 PLWH were included, with 106 older than 55. Both the intention-to-treat and the per-protocol analysis showed low rates of virologic failure, independent of the pre-switch anchor drug. At week 96, a significant increase in CD4
+ T cell count and in CD4+ /CD8+ ratio was observed, inversely correlated with baseline immune status. Fasting serum lipid profile, total body weight, BMI, and hepatic function were not affected by the switch, without new onset of metabolic syndrome or weight gain. Compared to baseline, we observed a renal function worsening which is worthy of further follow-up. Conclusion: BIC/FTC/TAF is an effective, safe, and well-tolerated switching strategy for PLWH, especially among those older than 55. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
5. Cellular Immune Profiling of Lung and Blood Compartments in Patients with SARS-CoV-2 Infection.
- Author
-
Santinelli, Letizia, Lazzaro, Alessandro, Sciarra, Francesca, Maddaloni, Luca, Frasca, Federica, Fracella, Matteo, Moretti, Sonia, Borsetti, Alessandra, Bugani, Ginevra, Alessandri, Francesco, Zullino, Veronica, Ruberto, Franco, Pugliese, Francesco, Sorrentino, Leonardo, Gianfrilli, Daniele, Isidori, Andrea, Venneri, Mary Anna, Mastroianni, Claudio M., Ceccarelli, Giancarlo, and d'Ettorre, Gabriella
- Subjects
MONONUCLEAR leukocytes ,LUNGS ,MONOCYTES ,T cells ,SARS-CoV-2 ,ADULT respiratory distress syndrome ,KILLER cells ,COVID-19 - Abstract
Background: SARS-CoV-2 related immunopathology may be the driving cause underlying severe COVID-19. Through an immunophenotyping analysis on paired bronchoalveolar lavage fluid (BALF) and blood samples collected from mechanically ventilated patients with COVID-19-associated Acute Respiratory Distress Syndrome (CARDS), this study aimed to evaluate the cellular immune responses in survivors and non-survivors of COVID-19. Methods: A total of 36 paired clinical samples of bronchoalveolar lavage fluid (BALF) mononuclear cells (BALF-MC) and peripheral blood mononuclear cells (PBMC) were collected from 18 SARS-CoV-2-infected subjects admitted to the intensive care unit (ICU) of the Policlinico Umberto I, Sapienza University Hospital in Rome (Italy) for severe interstitial pneumonia. The frequencies of monocytes (total, classical, intermediate and non-classical) and Natural Killer (NK) cell subsets (total, CD56
bright and CD56dim ), as well as CD4+ and CD8+ T cell subsets [naïve, central memory (TCM) and effector memory (TEM)], and those expressing CD38 and/or HLADR were evaluated by multiparametric flow cytometry. Results: Survivors with CARDS exhibited higher frequencies of classical monocytes in blood compared to non-survivors (p < 0.05), while no differences in the frequencies of the other monocytes, NK cell and T cell subsets were recorded between these two groups of patients (p > 0.05). The only exception was for peripheral naïve CD4+ T cells levels that were reduced in non-survivors (p = 0.04). An increase in the levels of CD56bright (p = 0.012) and a decrease in CD56dim (p = 0.002) NK cell frequencies was also observed in BALF-MC samples compared to PBMC in deceased COVID-19 patients. Total CD4+ and CD8+ T cell levels in the lung compartment were lower compared to blood (p = 0.002 and p < 0.01, respectively) among non-survivors. Moreover, CD38 and HLA-DR were differentially expressed by CD4+ and CD8+ T cell subsets in BALF-MC and in PBMC among SARS-CoV-2-infected patients who died from COVID-19 (p < 0.05). Conclusions: These results show that the immune cellular profile in blood and pulmonary compartments was similar in survivors and non-survivors of COVID-19. T lymphocyte levels were reduced, but resulted highly immune-activated in the lung compartment of patients who faced a fatal outcome. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
6. Alterations in the Expression of IFN Lambda, IFN Gamma and Toll-like Receptors in Severe COVID-19 Patients.
- Author
-
Sorrentino, Leonardo, Fracella, Matteo, Frasca, Federica, D'Auria, Alessandra, Santinelli, Letizia, Maddaloni, Luca, Bugani, Ginevra, Bitossi, Camilla, Gentile, Massimo, Ceccarelli, Giancarlo, Turriziani, Ombretta, Mastroianni, Claudio Maria, Antonelli, Guido, d'Ettorre, Gabriella, Pierangeli, Alessandra, and Scagnolari, Carolina
- Subjects
COVID-19 ,TOLL-like receptors ,GENE expression ,MONONUCLEAR leukocytes ,INTERFERON beta 1b ,INTERFERONS ,LACTATE dehydrogenase ,BACTERIAL diseases - Abstract
Contradictory results have been reported regarding interferon (IFN) lambda (λ1–3) and IFN gamma (γ) production in COVID-19 patients. To gain insight into the roles played by these IFNs in SARS-CoV-2 infection, IFNλ1–3 and IFNγ mRNA expression was evaluated in peripheral blood mononuclear cells (PBMCs) (n = 32) and in cells of paired bronchoalveolar lavages (BALs) (n = 12). Lower IFNλ1–3 values (p < 0.001 for IFNλ1 and 3 and p = 0.013 for IFNλ2) in the PBMCs of severely ill patients were found compared to healthy donors (n = 15). Reduced levels of IFNγ were also detected in patients' PBMCs (p < 0.01) and BALs (p = 0.041) compared to healthy donors. The presence of secondary bacterial infections was associated with decreased IFNλ amounts in PBMCs (p = 0.001, p = 0.015 and p = 0.003, respectively) but increased concentrations of IFNλ3 (p = 0.022) in BALs. Patients with alterations in C-reactive protein, lactate dehydrogenase and D-dimer levels had decreased IFNλ1 and 3 (p = 0.003 and p < 0.001) and increased IFNγ (p = 0.08) in PBMCs. Analyzing Toll-like receptors (TLRs) involved in IFN production, we found that TLR3 was highly expressed (p = 0.033) in patients with bacterial superinfections, while TLR7 and 8 (p = 0.029 and p = 0.049) were reduced in BALs of deceased patients. Overall, severe COVID-19 might be characterized by dysregulation in IFNγ, IFNλ and TLR3, 7 and 8 production. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients.
- Author
-
Trinchieri, Vito, Marazzato, Massimiliano, Ceccarelli, Giancarlo, Lombardi, Francesca, Piccirilli, Alessandra, Santinelli, Letizia, Maddaloni, Luca, Vassalini, Paolo, Mastroianni, Claudio Maria, and d'Ettorre, Gabriella
- Subjects
COVID-19 ,ADULT respiratory distress syndrome ,HYPOXEMIA ,KLEBSIELLA pneumoniae ,RESPIRATORY insufficiency ,LACTOBACILLUS rhamnosus - Abstract
Background: Although useful in the time-race against COVID-19, CPAP cannot provide oxygen over the physiological limits imposed by severe pulmonary impairments. In previous studies, we reported that the administration of the SLAB51 probiotics reduced risk of developing respiratory failure in severe COVID-19 patients through the activation of oxygen sparing mechanisms providing additional oxygen to organs critical for survival. Methods: This "real life" study is a retrospective analysis of SARS-CoV-2 infected patients with hypoxaemic acute respiratory failure secondary to COVID-19 pneumonia undergoing CPAP treatment. A group of patients managed with ad interim routinely used therapy (RUT) were compared to a second group treated with RUT associated with SLAB51 oral bacteriotherapy (OB). Results: At baseline, patients receiving SLAB51 showed significantly lower blood oxygenation than controls. An opposite condition was observed after 3 days of treatment, despite the significantly reduced amount of oxygen received by patients taking SLAB51. At 7 days, a lower prevalence of COVID-19 patients needing CPAP in the group taking probiotics was observed. The administration of SLAB51 is a complementary approach for ameliorating oxygenation conditions at the systemic level. Conclusion: This study proves that probiotic administration results in an additional boost in alleviating hypoxic conditions, permitting to limit on the use of CPAP and its contraindications. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.